Introduction
Accepted approaches to the management of patients presenting with an evolving myocardial infarction involve the use of angioplasty or thrombolytic therapy (streptokinase, activase, retavase, etc.) coadministered with both heparin and acetylsalicylic acid (aspirin) (Gensini et al., 1999; Gibson, 1999; Spinler et al., 2001 ). Whereas either angioplasty or administration of a thrombolytic agent is eective in restoring arterial blood¯ow, maintaining vessel patency depends upon adjunctive therapy directed at inhibition of thrombin generation and/or platelet reactivity. Several antiplatelet agents (abciximab, epti®batide, tiro®ban, ticlopidine, clopidogrel) , having mechanisms of action diering from that of aspirin, show ecacy in reducing the incidence of thrombotic occlusion after restoration of arterial blood ow (Spinler et al., 2001) .
Platelets serve an important role in arterial thrombosis and represent a predominant pharmacologic target for the prevention of reocclusion after successful recanalization of an occluded vessel. Although aspirin can modulate platelet reactivity, its antiplatelet potential is achieved as a result of inhibition of cyclo-oxygenase, essential for conversion of arachidonic acid to thromboxane A 2 . The latter serves as a platelet activator and arterial vasoconstrictor. Aspirin is eective in preventing ex vivo arachidonic acid-induced platelet aggregation, but lacks signi®cant antiaggregatory ecacy against other platelet agonists (5-HT, epinephrine, thrombin, plasmin, etc.). On the other hand, pharmacologic interventions directed against the platelet glycoprotein (GP) IIb/IIIa receptor are eective antiaggregatory agents regardless of the inciting agonist (Makkar et al., 1997) .thrombotic ecacy. Studies also were designed to explore the minimal eective dose of CRL42796 in combination with aspirin. Anaesthetized canines were subjected to electrolytic injury of the carotid or coronary arteries for induction of primary arterial thrombosis. The latter is de®ned as an occlusive thrombus secondary to arterial wall injury. Previous studies in our laboratory demonstrated that GPIIb/IIIa receptor antagonists are eective in preventing primary thrombus formation and maintaining vessel patency (Mickelson et al., 1990; Rote et al., 1994a) . Ex vivo platelet aggregation and bleeding times were measured. The results demonstrate that CRL42796 is an eective antithrombotic agent with a minimal tendency to induce signi®cant uncontrolled bleeding.
Methods

Guidelines for the use and care of experimental animals
The procedures used in this study are in accordance with the guidelines of the University of Michigan University Committee on the Use and Care of Animals and conform to the standards in The Guide for Care and Use of Laboratory Animals (NIH no. 86 ± 23) . The University of Michigan Unit for Laboratory Animal Medicine provided veterinary care.
Surgical preparation and model of vessel occlusion
Purpose-bred hound dogs, weighing 9 ± 12 kg, were anaesthetized with sodium pentobarbital (30 mg kg 71 , i.v.). The animals were intubated and ventilated with room air using a Harvard respirator (Harvard Apparatus, Inc., Holliston, MA, U.S.A.), adjusted to deliver a tidal volume of 30 ml kg 71 at a frequency of 12 breaths min
71
. A catheter was inserted into the right and left femoral veins for drug administration and blood sampling. Arterial blood pressure was recorded from the right femoral artery using a Millar 2 Mikro-tip catheter (Millar Instruments, Inc., Houston, TX, U.S.A.). A standard limb lead II electrocardiograph was recorded continuously to monitor heart rate. A calibrated ultrasonic¯ow probe (Model 2RB907, Transonic Systems Inc., Ithaca, NY, U.S.A.) was placed on the carotid artery and blood¯ow was monitored continuously. All physiologic parameters were recorded on a Grass polygraph interfaced to a MacLab (AD Instruments Pty Ltd, Castle Hill, Australia) data acquisition system and Macintosh 2 computer (Apple Computer, Inc., Cupertino, CA, U.S.A.).
An intravascular electrode was inserted through the wall of the carotid artery and positioned so that the noninsulated intraluminal portion of the electrode was in ®rm contact with the intimal surface of the vessel. An external adjustable constrictor was applied to the artery. The intravascular electrode and mechanical constrictor were positioned distal with respect to the¯ow probe. The mechanical constrictor on the carotid artery was constructed of stainless steel, shaped to ®t around the vessel. A nylon screw (2 mm in diameter) threaded through the C-shaped metal band was adjusted to decrease the circumference of the vessel thereby forming a regional stenosis. The vessel was narrowed to a point where the pulsatile¯ow pattern was reduced by 50% without altering the mean carotid artery blood¯ow.
Electrolytic injury to the intimal surface of the carotid artery was accomplished with the use of an intravascular electrode composed of a Te¯on-insulated, silver-coated, copper wire. Penetration of the vessel wall by the electrode was facilitated by attaching the tip of a 25-gauge hypodermic needle to the distal, non-insulated part of the electrode. The intravascular electrode was connected to the positive pole (anode) of a dual-channel square wave generator (Grass S88 stimulator and a Grass Constant Current Unit, Model CCU1A). The cathode was connected to a distant subcutaneous site. The current delivered to the vessel was monitored continuously on an ammeter and maintained at 300 mA for induction of carotid artery vessel wall injury, and 150 mA when used to induce deep vessel wall injury in the coronary artery. The anodal electrode was positioned to have the non-insulated portion (3 ± 4 mm) in intimate contact with the endothelial surface of the vessel. Proper positioning of the electrode in the vessel and evidence of vessel wall injury was con®rmed by visual inspection at the conclusion of each experiment. The presence of the external constrictor results in localized turbulent¯ow and mimics the presence of an atheromatous plaque in a diseased vessel. The combined presence of deep vessel wall injury and turbulent¯ow leads to the progression of platelet-dependent occlusive thrombus formation. The anodal current was terminated 30 min after arterial occlusion as indicated by the absence of blood¯ow. On the other hand, the anodal injury current was maintained for a maximum duration of 3 h if the vessel remained patent as evidenced by the presence of blood¯ow after which the anodal current was suspended. In the latter instance, a value of 180 min was used as the`time to occlusive thrombosis' for the purpose of statistical analysis.
Model of coronary artery thrombosis
The heart was exposed through a left thoracotomy at the sixth intercostal space and suspended in a pericardial cradle. A 1-cm segment of the left circum¯ex (LCX) coronary artery was exposed proximal to the ®rst obtuse marginal branch and instrumented with a Transonic 2 ultrasonic¯ow probe (Model 1.5RB, Transonic Systems Inc., Ithaca, NY, U.S.A.) for continuous monitoring of phasic coronary artery blood¯ow. Instrumentation of the canine coronary artery for induction of arterial thrombosis was similar to that described for the carotid artery. A ligature stenosis was placed around the LCX coronary artery such that the hyperemic response to a 10-s occlusion was reduced by 30%. Mean coronary artery blood¯ow was not aected by the stenosis. An intracoronary electrode was inserted through the LCX arterial wall so that the uninsulated portion was positioned against the endothelial surface. Deep vessel wall injury and occlusive arterial thrombosis was initiated via application of an anodal current (150 mA) to the intimal surface of the vessel.
Experimental protocol
Initially, the carotid artery was selected for our experimental model as it allows one vessel (the right carotid artery) to be used as a control and the other (the left carotid artery) to be used as a test vessel after the administration of CRL42796.
Previous studies have validated the 2-vessel model of thrombosis (Rote et al., 1993; 1994b Thrombus weight was determined after removal of the intact thrombus from the vessel wall. Ex vivo platelet aggregation determinations and tongue bleeding times were recorded at baseline, after completing the surgical preparation, 120 min and 225 min after placebo or drug administration. Heart rate, mean arterial blood pressure and phasic arterial blood¯ow were recorded continuously.
In a separate group of experiments, aspirin was administered orally at a dose of 4.6 mg kg
71
, 41 h and 17 h before the initiation of electrolytic injury of the vessel wall to assess the eects of combining low dose aspirin with CRL42796. Previous studies demonstrated that the aspirin dosing regimen mimics low dose aspirin and signi®cantly increases time to arterial thrombosis (Hennan et al., 2001) . The left carotid artery was subjected to deep vessel wall injury in the presence of low dose aspirin alone and the right carotid artery was subjected to deep vessel wall injury in the presence of a combination of low dose aspirin and CRL42796 (15 mg kg 71 loading dose +0.31 mg kg 71 min
). A similar experimental protocol to that described above was used to assess the eect of CRL42796 on prevention of LCX coronary artery thrombosis except separate groups of animals acted as controls and drug-treatments. Group 1 served as controls (saline-treated i.v.) 
Haematological measurements
Ex vivo platelet aggregation Blood (10 ml) was withdrawn from the right femoral vein into a plastic syringe containing 3.7% sodium citrate as the anticoagulant (1 : 10 citrate to blood; v v
71
). Platelet rich plasma (PRP) was obtained by collecting the supernatant from whole blood centrifuged at 1406g for 5 min. Subsequently, platelet poor plasma (PPP) was prepared from the same blood sample by further centrifugation at 20006g for 10 min. Ex vivo platelet aggregation was assessed at 378C with a four-channel platelet aggregometer (Bio-Data-PAP-4, Bio Data, Hatboro, PA, U.S.A.) by recording the increase in light transmission through a stirred suspension of PRP adjusted to 200,000 platelets ml
. Aggregation was induced with arachidonic acid (AA, 650 mM) or ADP (20 mM). A subaggregatory dose of epinephrine (550 nM) was used to prime the platelets before the agonists were added.
Tongue-template bleeding time Bleeding times were determined with the use of a Surgicutt device (International Technidyne Corporation, Edison, NJ, U.S.A.), that made a uniform incision 5 mm long and 1 mm deep on the upper surface of the tongue. The lesion was blotted with ®lter paper every 20 s until the transfer of blood to the ®lter paper ceased. 
Statistical analysis
The data are expressed as mean+s.e.m. Comparisons among the incidence of carotid or coronary artery occlusion in saline and drug-treated dogs were performed using a w 2 test. Changes in time to carotid or coronary artery thrombosis and thrombus weights between saline-and drug-treated animals were carried out using paired t-tests. Changes in time to thrombosis among saline-treated, aspirin-treated and aspirin plus CRL42796-treated animals were made using a one-way ANOVA followed by Student-Newman-Keuls multiple comparison test. Platelet aggregation values and bleeding times were compared to respective baseline values using a one-way ANOVA followed by Dunnet's post hoc analysis. P50.05 was considered statistically signi®cant for all comparisons.
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Results
Heart rate and mean arterial blood pressure were not dierent among treatment groups before administration of CRL42796. The intravenous administration of either CRL42796 or vehicle (0.9% sodium chloride solution) did not result in signi®cant dierences in heart rate and blood pressure compared to respective controls during electrolytic injury of the carotid or coronary artery (data not shown).
The eects of CRL42796 on the incidence of carotid artery thrombosis and time to occlusive thrombus development are shown in Table 1 Table 1 ). Thrombus weight did not dier signi®cantly between controls and animals receiving an infusion of CRL42796 at a rate of 0.31 mg kg 71 min
71
. However, when the infusion dose was increased to 0.69 mg kg 71 min 71 a signi®cant decrease in thrombus weight was observed. The decrease in thrombus weight was consistent with the observation that each of the ®ve vessels treated with the higher infusion dose of CRL42796 remained patent after 180 min of electrolytically induced vessel wall injury.
In animals pre-treated with aspirin (4.6 mg kg
) 41 and 17 hs before initiation of electrolytic injury, time to carotid artery thrombosis was increased signi®cantly (131.0+10.7 min) compared to saline-treated controls (47.6+8.9 min) (see Table 1 ). Despite an increase in the time to thrombosis, aspirin did not prevent the development of an occlusive carotid artery thrombus in any of the ®ve animals tested. When CRL42796 (15 mg kg 71 loading dose +0.31 mg kg 71 min 71 i.v.) was combined with low dose aspirin, three of the ®ve vessels tested did not occlude during 180 min of electrolytic injury. It is notable that similar results were observed in the absence of low dose aspirin (see Table  1 ). Therefore, it appears that combining low dose aspirin with CRL42796 does not provide additional protection against the development of occlusive arterial thrombosis. Low dose aspirin or a combination of low dose aspirin and CRL42796 did not produce a signi®cant change in thrombus weight compared to respective controls. Figure 2 illustrates the carotid artery blood¯ow in control or CRL42796-treated animals during induction of vessel wall injury. Time zero on the graph represents the initiation of the anodal current for induction of deep vessel wall injury. As indicated in Figure 2a , control animals exhibited a progressive decline in carotid artery blood¯ow to zero. The latter was accompanied by the development of an occlusive thrombus. In the presence of CRL42796 (15 mg kg 71 loading dose +0.31 mg kg 71 min 71 i.v.) a progressive decrease in blood¯ow was observed during electrolytic injury, however three of the ®ve carotid arteries remained patent throughout the 180 min duration of anodal current application. When the intravenous infusion of CRL42796 was increased to 0.69 mg kg 71 min 71 the carotid artery blood¯ow remained relatively stable during application of the electrolytic injury current and all vessels were patent at the end of 180 min at which point the anodal current was terminated (see Figure 2b ).
When aspirin (4.6 mg kg 71 741, 717 h p.o.) was combined with CRL42796 (15 mg kg 71 loading dose +0.31 mg kg 71 min 71 i.v.) carotid artery blood¯ow decreased progressively during electrolytic injury. However, despite the addition of aspirin to the treatment regimen only three of the ®ve vessels studied remained patent over the course of the experiment (see Figure 2c) .
The eect of CRL42796 on platelet aggregation in response to ADP (20 mM) and arachidonic acid (AA, 650 mM) from citrated whole blood is shown in Figure 3 (Figure 3b ), CRL42796 signi®cantly reduced ex vivo platelet responses to both ADP and AA. When animals were pretreated with aspirin (4.6 mg kg 71 741, 17 h p.o.), platelet responses to AA were inhibited at baseline indicating inhibition of platelet COX-1. In contrast, platelet responses to ADP were unchanged (see Figure 3c ). As anticipated, the addition of CRL42796 (15 mg kg 71 loading dose +0.31 mg kg 71 min 71 i.v.) signi®cantly reduced, but did not prevent, ex vivo platelet responses to ADP in aspirin-treated dogs, whereas ex vivo platelet responses to AA remained inhibited over the course of the experimental protocol.
Selected experiments were conducted to determine if platelet responses are altered by the use of citrate as an 
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In vivo antithrombotic activity of CRL42796 J.K. Hennan et al anticoagulant. Platelet responses to ADP and AA were assessed under conditions in which venous blood for the preparation of PRP and PPP was collected in syringes in which heparin served as the anticoagulant. Figure 4a illustrates the eects of CRL42796 (15 mg kg 71 loading dose +0.31 mg kg 71 min 71 i.v.) on platelet aggregation in response to AA and ADP when heparin was the anticoagulant. The platelet aggregation responses were reduced in the presence of the lower dose of CRL42796, however the changes were not statistically signi®cant. At the higher dose of CRL42796, a signi®cant reduction in ex vivo platelet reactivity was observed. In aspirin-treated animals (4.6 mg kg 71 741, 717 h p.o.), the use of heparin as an anticoagulant produced similar results as observed with citrate. AA-induced platelet aggregation was inhibited signi®cantly at baseline compared to non-aspirin treated controls and remained inhibited throughout the experimental protocol. ADP-induced platelet aggregation in aspirin-treated dogs was similar at baseline with heparin as the anticoagulant and the addition of CRL42796 signi®cantly reduced platelet reactivity (see Figure  4c) .
The eects of CRL42796 on tongue bleeding time are shown in Figure 5 . At the lower infusion dose of CRL42796 there was a trend towards an increase in tongue bleeding time; however, the change was not statistically signi®cant from baseline (Figure 5a ). When the infusion dose of CRL42796 was increased to 0.69 mg kg 71 min
71
, there was a related signi®cant increase in tongue bleeding time at 120 and 240 min after initiating the drug infusion (see Figure 5b) . Bleeding times exceeding 10 min were recorded as 10 min for statistical analysis.
Aspirin (4.6 mg kg 71 741, 717 h p.o.) did not produce a signi®cant increase in bleeding time at baseline compared to non-treated control animals ( Figure 5c ). Table 2 ). Thrombus weight was not signi®cantly dierent among control and CRL42796-treated animals.
The in vivo antithrombotic eects of CRL42796 were examined in the canine coronary artery subjected to deep vessel wall injury. The blood¯ow results are summarized in Figure 6 . In the control group (n=5), coronary artery blood ow decreased progressively commencing with the induction of electrolytic injury of the vessel wall. Occlusive thrombosis developed in each of the vessels within 90.8+10.4 min. Two separate groups of ®ve animals each received CRL42796 commencing before induction of vessel wall injury. As before, the drug was administered as an intravenous loading dose of 15 mg kg 71 followed by an infusion of either 0.31 mg kg 71 min 71 (n=5) or 0.69 mg kg 71 min 71 (n=5). As indicated in Table 2 , one of ®ve vessels occluded in the group receiving the low infusion dose whereas all vessels remained patent in the group given the high infusion dose. Although all vessels remained patent in the high infusion dose group, the time to occlusion is listed in Table 2 as 180+0 min for the purpose of statistical analysis.
Occlusive and non-occlusive thrombi were found in the injured coronary arteries. In the saline-treated control group, occlusive thrombi were present in each of the ®ve arteries and ®rmly attached to the site of vessel injury. One of ®ve vessels 
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In vivo antithrombotic activity of CRL42796 J.K. Hennan et al in the low dose infusion group showed the presence of an occlusive thrombus while occlusive thrombi were not found in any of the vessels in the high dose infusion group. The thrombus weights did not dier among the groups despite the fact that control vessels occluded whereas nine of ten vessels from the animals treated with CRL42796 remained patent. The apparent discrepancy between thrombus weight and vessel patency relates to the fact that¯ow was preserved in the presence of the antiplatelet agent. Inhibition of the platelet GPIIb/IIIa receptor prevents the formation of an occlusive platelet plug and results in a thrombus mass that extends in a retrograde direction without occluding the vessel lumen. Prolongation in the time to thrombosis or its prevention provides an extended period over which the`tail' of the thrombus can propagate before the experiment is terminated. In the control group, platelet accretion results in the rapid formation of a ®rm, occlusive platelet plug with little opportunity for extension beyond the site of vessel wall injury before¯ow declines to zero at which point the vessel is removed for determination of thrombus weight.
Ex vivo platelet responses in citrated whole blood from the coronary artery thrombosis protocol are shown in Figure 7 . PRP prepared from blood of control (saline-treated) dogs showed typical ex vivo aggregation responses to AA ( Figure  7a ) or ADP (Figure 7b ) over the entire time course of the experimental protocol. Treatment with CRL42796 signi®-cantly reduced platelet responses to both AA and ADP at 120 and 225 min after administration CRL42796 in both the high and low dose regimens (see Figure 7) . Ex vivo platelet aggregation determinations also were performed with heparin as the anticoagulant. As shown in Figure 8 , ex vivo platelet responses to AA (Figure 8a ) and ADP ( Figure 8b ) were reduced after administration of CRL42796 compared to 
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The eects of CRL42796 on bleeding time during the coronary artery thrombosis experiments are shown in Figure   9 . After a loading dose of CRL42796 (15 mg 
Discussion
The experimental model of arterial thrombosis used in this study was validated previously (Romson et al., 1980; Rote et al., 1993; 1994b) . The unique feature of the model is that arterial thrombosis develops spontaneously in response to deep vessel wall injury. The latter is the dominant in¯uence and by itself can lead to thrombosis. The vascular injury is induced by an anodal current applied to the endothelial surface of the vessel resulting in exposure of subendothelial collagen and other components capable of increasing platelet reactivity and subsequent activation of the coagulation cascade. The development of a deep arterial wall lesion and exposure of subendothelial structures allows the previously nonthrombotic vascular surface to become prothrombotic. The imposition of a critical stenosis immediately distal to the site of vessel wall injury contributes to the thrombotic process by increasing the degree of turbulence. The disruption in the normal pattern of blood¯ow further impairs endothelial function and forms countercurrents and local pockets of stasis. Turbulence and stasis disrupt the normal pattern of laminar¯ow thereby allowing platelets to encounter the prothrombotic surface of the injured vessel wall. Within a brief period after endothelial injury, platelets begin to form a monolayer at the site where subendothelial elements encounter the¯owing blood. Subsequently the progressive accretion of platelets, formation of ®brin and entrapment of cellular blood components leads to the development of a platelet-rich thrombus supported by a ®rm ®brin network (Romson et al., 1980; Bush & Shebuski, 1990) . A detailed electron-microscopic examination of the electrolytically-induced vessel wall injury and cellular composition of the thrombus, plus the bene®ts derived from inhibition of in vivo platelet reactivity has been published (Romson et al., 1980) . Many experimental models have been used for the study of antithrombotic drugs (Bush & Shebuski, 1990) . In the electrolytic injury model, development of an occlusive thrombus proceeds spontaneously in response to vessel wall injury. The ability to control the size of the injured area, plus the intensity and duration of the electrolytic anodal current, make the model highly reproducible and dependent upon natural physiological processes that lead to thrombus formation. The interaction between the injured vessel wall Data represent mean+s.e.mean for n=5 or 6 experiments. *Indicates a signi®cant dierence from saline-treated control (P50.05).
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In vivo antithrombotic activity of CRL42796 J.K. Hennan et alknown to occur clinically provides a reliable model for the evaluation of antiplatelet agents for the prevention of occlusive arterial thrombosis.
During the complex platelet response to vessel wall injury, multiple mediators contribute to platelet activation and aggregation including ®brinogen, thrombin, ADP, thromboxane A2 and serotonin (Marcus, 1994) . Conventional antithrombotic agents such as aspirin, prostacyclin, thromboxane synthase inhibitors and thromboxane receptor antagonists directly target single mediators of platelet activation. Because the ®nal common pathway in thrombus development involves platelets binding to ®brinogen via the GPIIb/IIIa receptor, inhibition of this ®nal pathway provides an eective antithrombotic eect that encompasses inhibition of platelet activation in response to numerous platelet agonists. The present study demonstrates the in vivo ecacy of the platelet GPIIb/IIIa receptor antagonist CRL42796 in an electrolytic injury model of the canine carotid and coronary artery.
The intravenous threshold dose of CRL42796 for preventing arterial thrombosis required a loading dose of 15 mg kg . Both infusion rates maintained vessel patency with the higher rate being more eective. There was a progressive decline in carotid artery blood¯ow over the course of the experiment with the lower infusion dose that was not observed when the dose was increased. Thrombi recovered from the vessels subjected to electrolytic injury during treatment with CRL42796 were smaller than those retrieved from control vessels which correlates well with the inhibition of occlusive thrombus formation. However, these results should be interpreted carefully as the thrombi in control arteries were in situ for a longer period and had an opportunity to increase in size. It is important to recall that arterial thrombi propagate in a retrograde direction due to the presence of an occlusive plug and stasis. The events leading to thrombus propagation would be eliminated or markedly reduced under conditions in which blood¯ow is maintained, albeit reduced, after treatment with an antiplatelet agent.
Ex vivo platelet responses from citrate anticoagulated whole blood were only partly correlated with the inhibition of arterial thrombosis. The high and low infusion rate of CRL42796 completely inhibited platelet responses as long as the infusion was maintained; however, two of the ®ve vessels tested at the lower infusion dose developed occlusive thrombosis. Previous studies have indicated that citrated whole blood platelet responses after treatment with GPIIb/ IIIa receptor antagonists do not correlate with the in vivo prevention of arterial thrombosis (Phillips et al., 1997; Rebello et al., 1998) . The discrepancy between the in vitro platelet aggregation responses conducted in the presence of citrate and the in vivo results relates to a decrease in the plasma ionized calcium concentration due to chelation with citrate (Phillips et al., 1997; Rebello et al., 1998) . Calcium is essential for the formation of the GPIIb/IIIa heterodimer complex (Lam, 1992) and for the interaction between the GPIIb/IIIa receptor and ®brinogen (Steiner et al., 1989) . When the calcium concentration of platelet rich plasma is decreased by citrate, binding of the GPIIb/IIIa receptor antagonist is enhanced resulting in an overestimation of the antiplatelet ecacy of the compound. In animals treated with the lower infusion dose of CRL42796 (0.31 mg kg 71 min 71 ) platelet responses in PRP prepared from heparin anticoagulated whole blood were reduced, but not signi®cantly inhibited. With the lower infusion dose of CRL42796 40% of the vessels occluded. Thus, it appears that ex vivo platelet aggregation responses conducted in heparin anticoagulated PRP are better correlated more dependably with the in vivo observations on thrombosis. At the higher infusion dose of CRL42796 (0.69 mg kg 71 min
71
) platelet responses from heparin anticoagulated PRP were signi®cantly reduced and thrombus formation was prevented. Thus, eective antithrombotic doses of GPIIb/IIIa receptor antagonists may be extrapolated more accurately from ex vivo platelet aggregation responses performed in PRP in which the physiologic concentration of ionized calcium is maintained.
An interesting aspect of the platelet inhibitory action of CRL42796 was that it dissipated rapidly upon discontinuing the drug infusion and vessels occluded within 60 min of terminating the infusion (data not shown). Thus, CRL42796 displays a rapid-on and rapid-o pharmacological pro®le that may oer an improved safety factor in those clinical situations where increased bleeding might occur. Other GPIIb/IIIa receptor antagonists such as 7E3 (Bates et al., 1992; Rote et al., 1994c) , DMP-728 (Lucchesi et al., 1994) , and SM-20302 (Huang et al., 1999) result in extended maintenance of vessel patency despite the fact that ex vivo platelet aggregation responses return to baseline values. There are other factors to consider involving a time-dependent decrease in the thrombogenicity of the injured vessel wall thus allowing preservation of blood¯ow in the presence of normal platelet function. The pharmacokinetic pro®le of CRL42796 may be of value when used over a period of 24 ± 48 h to provide sucient time for vessel wall`passivation' to occur before terminating the infusion (Bates et al., 1992) .
Bleeding times have been reported to be a poorly reproducible determinant of platelet reactivity (ChanningRodgers & Levine, 1990) . In the present study, tonguebleeding times correlated with the inhibition of platelet activity and thrombosis. At the lower infusion dose of CRL42796, we did not observe a signi®cant increase in bleeding and occlusive thrombus formation was not prevented completely. At the higher infusion dose, tonguebleeding time was increased signi®cantly and occlusive thrombosis was inhibited. The results suggest that bleeding time may be a useful measure for the ability of a platelet receptor antagonist to inhibit arterial thrombosis.
The combination of CRL42796 and aspirin failed to produce an additive or synergistic antithrombotic eect. Aspirin was administered orally at 741 and 717 h before commencing the experimental protocol. Aspirin is known to irreversibly inhibit platelet derived COX-1 and to reversibly inhibit the constitutive and inducible forms of endothelial COX-2 (Vane, 1971) .
We previously demonstrated that the dosing regimen for aspirin as used in this study inhibits platelet responses to arachidonic acid while allowing endothelial sources of COX-2 to regenerate and produce prostacyclin (Hennan et al., 2001) . Aspirin alone signi®cantly increased time to thrombosis in the current study; however, it did not prevent occlusive arterial thrombus formation. This result is consistent with those observed previously in this laboratory using the same experimental model and aspirin-dosing regimen (Hennan et al., 2001) . When aspirin was combined with the low infusion dose of CRL42796, no additional antithrombotic bene®t was observed. Time to thrombosis remained relatively the same and two of the ®ve vessels subjected to electrolytic injury occluded. CRL42796 administered at the same dose in the absence of aspirin resulted in occlusion in two of ®ve vessels. An analysis of the carotid artery blood¯ow in animals treated with aspirin and CRL42796 revealed a rapid decline in¯ow over the 180 min of electrolytic injury. In comparison to treatment with CRL42796 alone, the addition of aspirin appeared to accelerate the reduction in blood¯ow that occurs in response to deep vessel wall injury. The underlying mechanism to account for this observation remains unknown and is deserving of further study. It is interesting to note that bleeding times were unchanged in the presence of aspirin and CRL42796, possibly indicating a change in vascular tone in the tongue. On the other hand, one might question the bene®t to be derived from the addition of aspirin to a treatment regimen involving the use of a platelet GPIIb/IIIa receptor antagonist. The antiplatelet eect of aspirin is directed against the enzymatic conversion of arachidonic acid to thromboxane A 2 in which the latter serves as an agonist for platelet aggregation. Aspirin does not prevent platelet aggregation by other agonists present in vivo during vessel wall injury. Furthermore, since activation of the GPIIb/ IIIa receptor is the ®nal common pathway for platelet aggregation, it is unlikely that aspirin would serve as an eective adjunctive agent.
In conclusion, CRL42796 eectively inhibits ex vivo platelet aggregation in response to AA and ADP and only marginally increases bleeding time. CRL42796 is an eective in vivo intravenous antithrombotic agent for preventing occlusive arterial thrombosis in response to deep vessel wall injury when used as the sole intervention. Ex vivo platelet aggregation responses conducted in the presence of a physiologic plasma ionized calcium concentration is a more accurate indicator of a drug's antithrombotic potential compared to ex vivo studies done in PRP anticoagulated with citrate. As the dose of CRL42796 is increased bleeding time increases; however, careful control of the plasma concentration may help to avoid excessive peak plasma levels that contribute to excessive bleeding. The combination of low dose CRL42796 with aspirin did not provide a further bene®t. Furthermore, the addition of aspirin appears to paradoxically reduce the ecacy of CRL42796. The mechanism to account for this ®nding is not apparent and is deserving of further investigation.
